JPMorgan Chase & Co. Lowers Clorox (NYSE:CLX) Price Target to $150.00

Clorox (NYSE:CLX) had its price objective decreased by JPMorgan Chase & Co. from $158.00 to $150.00 in a report issued on Monday morning, Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

Several other equities research analysts have also recently issued reports on CLX. Barclays reduced their target price on Clorox from $132.00 to $122.00 and set an underweight rating on the stock in a report on Friday, July 19th. Citigroup reduced their price objective on Clorox from $150.00 to $145.00 and set a neutral rating on the stock in a research note on Wednesday, July 10th. Jefferies Financial Group raised Clorox from an underperform rating to a hold rating and set a $145.00 price objective on the stock in a research note on Tuesday, March 26th. DA Davidson reaffirmed a neutral rating and issued a $162.00 price objective on shares of Clorox in a research note on Wednesday, April 17th. Finally, Argus raised Clorox to a hold rating in a research note on Tuesday, June 4th. Six investment analysts have rated the stock with a sell rating and fourteen have given a hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of Hold and a consensus target price of $142.13.

Clorox Stock Performance

NYSE:CLX opened at $133.35 on Monday. The stock has a 50-day moving average price of $133.73 and a 200 day moving average price of $142.70. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 9.73. Clorox has a 12-month low of $114.68 and a 12-month high of $169.14. The stock has a market capitalization of $16.56 billion, a P/E ratio of 69.09, a P/E/G ratio of 1.96 and a beta of 0.39.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.38. Clorox had a net margin of 3.33% and a return on equity of 302.49%. The business had revenue of $1.81 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same period last year, the firm posted $1.51 EPS. The company’s revenue was down 5.3% on a year-over-year basis. Equities research analysts forecast that Clorox will post 5.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Clorox

Several hedge funds have recently bought and sold shares of CLX. Venturi Wealth Management LLC grew its position in Clorox by 308.5% in the 1st quarter. Venturi Wealth Management LLC now owns 192 shares of the company’s stock valued at $29,000 after acquiring an additional 145 shares during the last quarter. Northwest Financial Advisors bought a new position in Clorox in the 4th quarter valued at $29,000. Core Wealth Advisors Inc. bought a new position in Clorox in the 4th quarter valued at $29,000. First United Bank & Trust bought a new position in Clorox in the 4th quarter valued at $31,000. Finally, GoalVest Advisory LLC bought a new position in Clorox in the 1st quarter valued at $31,000. Institutional investors own 78.53% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.